Table 3:
BCMA CAR-Ts
| Drug | Trial ID | Patient Population | Regimen | Phase | n | Median Prior Lines (Range) | ORR (%) | ≥VGPR (%) | PFS (months) | CRS Rate | ICANS Rate | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idecabtagene vicleucel (bb2121, ide-cel, Abecma) | NCT03361748 (KarMMa-2) | RRMM | Monotherapy | 2 | 128 | 6 (3–16) | 73 | 53 | 8.8 | 78% grade 1 or 2 5% grade 3 or 4 | 15% grade 1 or 2 3% grade 3 or 4 | 137–139 |
| Ciltacabtagene autoleucel (JNJ-68284528, cilta-cel) | NCT03548207 (CARTITUDE-1) | RRMM | Monotherapy | 1/2 | 97 | 6 (3–18) | 98 | 95 | 61% at 24-months | 90% grade 1 or 2 5% grade 3 or 4 | 14% grade 1 or 2 2% grade 3 or 4 | 147 |
| NCT04133636 (CARTITUDE-2) | 1–3 prior lines | Monotherapy | 2 | 20 | 2 (1–3) | 95 | 95 | NR | 85% grade 1 or 2 10% grade 3 or 4 | 15% grade 1 or 2 0% grade 3 or 4 | 148 | |
| Orvacabtagene autoleucel (JCARH125, orva-cel) | NCT03430011 (EVOLVE) | RRMM | Monotherapy | 1/2 | 62 | 7 (2–24) | 92 | 68 | NR | 85% grade 1 or 2 3% grade 3 or 4 | 10% grade 1 or 2 3% grade 3 or 4 | 149–151 |
| CT053 | NCT03716856 NCT03302403 NCT03380039 | RRMM | Monotherapy | 1 | 24 | 4.5 (2–11) | 88 | NR | NR | 63% grade 1 or 2 0% grade 3 or 4 | 8% grade 1 or 2 4% grade 3 or 4 | 152–153 |
| MCARH171 | NCT03070327 | RRMM | Monotherapy | 1 | 11 | 6 (4–14) | 64 | NR | NR | 40% grade 1 or 2 20% grade 3 or 4 | 10% grade 1 or 2 0% grade 3 or 4 | 154 |
Abbreviations: ORR: Overall response rate; VGPR: Very good partial response; PFS: progression-free survival; CRS: Cytokine release syndrome; ICANS: Immune effector cell-associated neurotoxicity syndrome; RRMM: relapsed refractory multiple myeloma; NR: not reported.